SCHEDULE: Lynx1 Capital Takes 37.1% Stake in Neuphoria Therapeutics

Lynx1 Capital Management LP and Weston Nichols have disclosed a 37.1% beneficial ownership stake in Neuphoria Therapeutics Inc., citing undervaluation and potential strategic engagement.

Summary

• Lynx1 Capital Management LP and Weston Nichols (the "Reporting Persons") have filed a Schedule 13D, disclosing beneficial ownership of Neuphoria Therapeutics Inc. (the "Company").
• The Reporting Persons collectively beneficially own 875,328 shares of Common Stock, representing 37.1% of the Company's outstanding shares.
• The shares were acquired for approximately $4,524,327, funded from the general working capital of Lynx1 Master Fund LP.
• The Reporting Persons believe the Company's securities are undervalued and represent an attractive investment opportunity.
• They intend to review their investment continuously and may engage with the Company's management and board regarding operations, management, board composition, capital structure, sale transactions, dividend policies, and strategic plans.
• Transactions in the past 60 days included significant sales in August and September 2025, followed by substantial purchases in October 2025, culminating in the current beneficial ownership.

Sentiment

Score: 7

Explanation: The filing indicates an activist investor, Lynx1 Capital Management LP, has taken a significant 37.1% stake in Neuphoria Therapeutics Inc., believing the shares are undervalued and represent an attractive investment opportunity. This suggests potential for positive strategic changes and value creation through active engagement with management and the board.

Positives

• Reporting Persons believe Neuphoria Therapeutics Inc. securities are undervalued, suggesting potential for future appreciation.
• The acquisition is viewed as an attractive investment opportunity by a significant institutional investor.
• Potential for active engagement with management and the board could lead to strategic enhancements, improved corporate governance, and increased shareholder value.

Negatives

• The filing itself does not present explicit negatives about the company's performance, but the investor's belief in undervaluation implies current market perception or operational efficiency may be suboptimal.
• Significant selling activity by the Reporting Persons in August and September 2025 at higher prices than the subsequent large purchases in October 2025 could indicate prior concerns or a shift in investment thesis.

Risks

• The Reporting Persons may change their intentions regarding their investment and engagement with the Company at any time.
• Future actions, including increasing or decreasing their position, are contingent on various factors such as the Company's financial position, strategic direction, overall market conditions, and other investment opportunities.
• Positions in the shares of Common Stock may be held in margin accounts, introducing leverage risk to the investment.

Future Outlook

The Reporting Persons intend to continuously review their investment in Neuphoria Therapeutics Inc. and may increase or decrease their position based on various factors. They plan to engage with the Company's management and board to discuss operations, management, board composition, capital structure, potential sale transactions, dividend policies, and strategic plans, with the aim of exploring and developing proposals for value creation.

Management Comments

• "The Reporting Persons acquired the securities reported herein because they believe the securities are undervalued and represent an attractive investment opportunity."
• "The Reporting Persons may communicate with the Company's management and board of directors... about... the Company's operations, management, Board composition, ownership, capital or corporate structure, sale transactions, dividend and buyback policies, strategy and plans..."

Industry Context

This Schedule 13D filing signals an activist investment in Neuphoria Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such significant stakes by activist investors often precede periods of increased scrutiny on company performance, strategic reviews, and potential corporate governance changes, which are common in industries facing intense R&D cycles, competitive pressures, or M&A consolidation.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if activist engagement leads to positive strategic changes, but also uncertainty regarding the outcome of such engagement.
• Management and Board: Will likely face increased pressure and engagement from Lynx1 Capital regarding company strategy, operations, and governance, potentially leading to changes in direction or personnel.

Next Steps

• Reporting Persons may communicate with Neuphoria Therapeutics' management and board regarding operations, management, board composition, capital structure, and strategic plans.
• Reporting Persons may increase or decrease their position in the Company through open market or private transactions.
• Reporting Persons may explore and prepare for various plans and actions, and propose transactions, including those that may affect their beneficial ownership or economic exposure.

Key Dates

Recommendation

The filing reveals a substantial 37.1% beneficial ownership by an activist investor, Lynx1 Capital, who believes Neuphoria Therapeutics Inc. is undervalued. This signals potential for strategic changes and value creation through active engagement with the company's management and board. However, specific plans or outcomes of this engagement are not yet defined. Therefore, a 'hold' recommendation is prudent, advising investors to monitor developments closely for concrete actions or proposals that could significantly impact the company's trajectory and valuation.

Keywords

Neuphoria Therapeutics, Lynx1 Capital Management, Weston Nichols, Schedule 13D, Beneficial Ownership, Activist Investor, Undervalued Stock, Corporate Governance, Strategic Investment